Jamjoom Pharmaceuticals Factory Co.

Results Flash Note Q3-25



Revenue came below market expectations; improved sales and improved margin profile still delivered a Y/Y net income growth

Jamjoom posted a Q3-25 net income of SAR 106.7mn, at a growth of 12.3% Y/Y, while down 19.2% Q/Q mainly as a result of its sequential sales cycle. Results missed our and market forecasts of SAR 117.3mn and SAR 115.2mn by -9.0% and -7.4% respectively. Revenues reported at SAR 342.3mn were up 4.5% Y/Y and down 13.6% Q/Q (-8.7% deviation). Geographic sales were supported by growth in North Africa & Others while KSA sales were down marginally by 2% Y/Y. Margins displayed healthy improvement on a Y/Y scale as gross margins of 60.9% increase by 160bps while EBIT margins of 32.1% increased 320bps. Jamjoom remains strategically active in its product expansion campaigns via licensing & supply partnerships with other firms, as well as a consistent product pipeline. At current prices, at a forward FY25E PE of 25x we view that the visible positives of the stock are reflected into current valuations. We retain our "Neutral" recommendation on the stock with a TP of SAR 167.2/share.

- Jamjoom posted a net income of SAR 106.7mn during the quarter, up 12.3% Y/Y and down 19.2% Q/Q as a result of its natural sales cycle. Bottom line was reported lower than our forecasted SAR 117.3mn at a deviation of -9.0%, and lower than the market consensus of SAR 115.2mn at a deviation of -7.4%. While our estimated net margin was in line with the reported 31.2%, our deviation was mainly owed to the miss in revenue estimates. Y/Y performance was mainly as a result of higher revenue and improved margin profile.
- Top line was reported at SAR 342.3mn, at a growth of 4.5% Y/Y; yet down 13.6%, likely as a result of Jamjoom's natural quarterly sales cycle. Sales performance was driven by new brand additions, price revisions, as well as increased volumes. While sales from KSA was down slightly by 2% Y/Y, positive revenue performance was delivered via increase sales across other geographies (mostly from North Africa & Others). Top line missed our estimates of SAR 374.7mn by -8.7%, and the market consensus of SAR 367.9mn by -7.0%.
- Gross profits reached SAR 208.5mn at a growth of 7.3% Y/Y, yet seasonally sequentially down by 16.8%. This came below our estimates of SAR 233.6mn at a deviation of -10.7%, mainly due to the top line miss, but also exasperated by GP margins at 60.9%, against our estimate of 62.3% at a deviation of -140bps. GP margin, however, improved 160bps Y/Y while seasonally down 240bps Q/Q. Cost of sales was reported nearly flat Y/Y despite higher revenues, as a result of a focus on high value brand sales.
- Operating profit (considering other income & expenses) was recorded at SAR 109.9mn, up 15.9% Y/Y and down 18.8% Q/Q. This came below our estimate of SAR 120.6mn by -8.9%, despite being in line with forecasted operating margins reported at 32.1%. OP margins of 32.1% were reported 310bps higher Y/Y, while down 210bps Q/Q. Notably, selling and distribution at SAR 74.2mn was up 9% to support commercial expansions.

AJC view and valuation: Jamjoom remains a strategically active firm, as it seeks to expand its product portfolio through 'license and supply' partnerships, with high value launches expected to kick off by Q4-26. Its consistent product launch pipeline also remains a growth driver for the firm's prospects. However, we believe that product diversification into competitive areas could challenge its margin profile. We expect that much of the expected positives of the stock are priced in at current prices at a forward FY25E PE of 25x. We retain our "Neutral" recommendation on the stock with a TP of SAR 167.2/share.

Results Summary

SAR mn	Q3-24	Q2-25	Q3-25	Change Y/Y	Change Q/Q	Deviation from AJC Estimates
Revenue	327.6	396.2	342.3	4.5%	-13.6%	-8.7%
Gross Profit	194.4	250.8	208.5	7.3%	-16.8%	-10.7%
Gross Margin	59.4%	63.3%	60.9%	-	-	-
EBIT	94.9	135.4	109.9	15.9%	-18.8%	-8.9%
Net Profit	95.0	132.0	106.7	12.3%	-19.2%	-9.0%
EPS	1.36	1.89	1.52	-	-	-

Source: Company Reports, AlJazira Capital Research

Recommendation	Neutral
Target Price (SAR)	167.2
Upside / (Downside)*	4.8%

Source: Tadawul *prices as of 22nd of October 2025

Key Financials

SARmn (unless specified)	FY22	FY23	FY24	FY25E
Revenues	917	1,101	1,318	1,509
Growth %	24.6%	20.1%	19.7%	14.5%
Gross profit	594	704	821	936
EBIT	233	313	381	464
Net Income	171	292	357	453
Growth %	0.35%	70.7%	21.9%	27.1%
EPS	2.45	4.18	5.09	6.43
DPS	2.1	1.00	2.55	3.60

Source: Company reports, Aljazira Capital Research

Key Ratios

	FY22	FY23	FY24	FY25E
Gross Margin	64.8%	64.0%	62.2%	62.0%
Oper. Margin	25.7%	28.5%	28.9%	30.8%
Net Margin	18.7%	26.6%	27.0%	30.0%
P/E (x)	-	-	30.3	24.8
P/B (x)	-	-	7.2	6.7
EV/EBITDA (x)	-	-	26.6	20.2
Dividend Yield	-	-	1.7%	2.3%

Source: Company reports, Aljazira Capita Research

Key Market Data

Market Cap(bn)	10.8
YTD%	4.9%
52 week (High)/(Low)	134/183.8
Share Outstanding (mn)	70

Source: Company reports, Aljazira Capital Research

Price Performance



Source: Tadwaul, Aljazira Capital Research

Senior Equity Analyst

Ibrahim Elaiwat

+966 11 2256115

i.elaiwat@Aljaziracapital.com.sa



Head of Sell-Side Research - Director Jassim Al-Jubran +966 11 2256248 j.aljabran@aljaziracapital.com.sa

RESEARCH

AlJazira Capital, the investment arm of Bank AlJazira, is a Shariaa Compliant Saudi Closed Joint Stock company and operating under the regulatory supervision of the Capital Market Authority. AlJazira Capital is licensed to conduct securities business in all securities business as authorized by CMA, including dealing, managing, arranging, advisory, and custody. AlJazira Capital is the continuation of a long success story in the Saudi Tadawul market, having occupied the market leadership position for several years. With an objective to maintain its market leadership position, AlJazira Capital is expanding its brokerage capabilities to offer further value-added services, brokerage across MENA and International markets, as well as offering a full suite of securities business.

FERMINOLOGY RATING

- Overweight: This rating implies that the stock is currently trading at a discount to its 12 months price target. Stocks rated "Overweight" will typically provide an upside potential of over 10% from the current price levels over next twelve months.
- Underweight: This rating implies that the stock is currently trading at a premium to its 12 months price target. Stocks rated "Underweight" would typically decline by over 10% from the current price levels over next twelve
- Neutral: The rating implies that the stock is trading in the proximate range of its 12 months price target. Stocks rated "Neutral" is expected to stagnate within +/- 10% range from the current price levels over next twelve
- Suspension of rating or rating on hold (SR/RH): This basically implies suspension of a rating pending further analysis of a material change in the fundamentals of the company.

Disclaimer

The purpose of producing this report is to present a general view on the company/economic sector/economic subject under research, and not to recommend a buy/sell/hold for any security or any other assets. Based on that, this report does not take into consideration the specific financial position of every investor and/or his/her risk appetite in relation to investing in the security or any other assets, and hence, may not be suitable for all clients depending on their financial position and their ability and willingness to undertake risks. It is advised that every potential investor seek professional advice from several sources concerning investment decision and should study the impact of such decisions on his/her financial/legal/tax position and other concerns before getting into such investments or liquidate them partially or fully. The market of stocks, bonds, macroeconomic or microeconomic variables are of a volatile nature and could witness sudden changes without any prior warning, therefore, the investor in securities or other assets might face some unexpected risks and fluctuations. All the information, views and expectations and fair values or target prices contained in this report have been compiled or arrived at by Al-Jazira Capital from sources believed to be reliable, but Al-Jazira Capital has not independently verified the contents obtained from these sources and such information may be condensed or incomplete. Accordingly, no representation or warranty, express or implied, is made as to, and no reliance should be placed on the fairness, accuracy, completeness or correctness of the information and opinions contained in this report. Al-Jazira Capital shall not be liable for any loss as that may arise from the use of this report or its contents or otherwise arising in connection therewith. The past performance of any investment is not an indicator of future performance. Any financial projections, fair value estimates or price targets and statements regarding future prospects contained in this document may not be realized. The value of the security or any other assets or the return from them might increase or decrease. Any change in currency rates may have a positive or negative impact on the value/return on the stock or securities mentioned in the report. The investor might get an amount less than the amount invested in some cases. Some stocks or securities maybe, by nature, of low volume/trades or may become like that unexpectedly in special circumstances and this might increase the risk on the investor. Some fees might be levied on some investments in securities. Aljazira Capital, its employees, one or more of its affiliates, or its clients may have investments in the securities or assets referred to in this report. This report has been produced independently and separately by the Research Division at Al-Jazira Capital and no party (in-house or outside) who might have interest whether direct or indirect have seen the contents of this report before its publishing, except for those whom corporate positions allow them to do so, and/or thirdparty persons/institutions who signed a non-disclosure agreement with Al-Jazira Capital. Funds managed by Al-Jazira Capital and its subsidiaries for third parties may own the securities that are the subject of this document. Al-Jazira Capital or its subsidiaries may own securities in one or more of the aforementioned companies, and/or indirectly through funds managed by third parties. The Investment Banking division of Al-Jazira Capital maybe in the process of soliciting or executing fee earning mandates for companies that is either the subject of this document or is mentioned in this document. One or more of Al-Jazira Capital board members or executive managers could be also a board member or member of the executive management at the company or companies mentioned in this report, or their associated companies. No part of this report may be reproduced whether inside or outside the Kingdom of Saudi Arabia without the written permission of Al-Jazira Capital. Persons who receive this report should make themselves aware, of and adhere to, any such restrictions. By accepting this report, the recipient agrees to be bound by the foregoing limitations.

Asset Management | Brokerage | Investment Banking | Custody | Advisory

Head Office: King Fahad Road, P.O. Box: 20438, Riyadh 11455, Saudi Arabia, Tel: 011 2256000 - Fax: 011 2256068